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Polypharmacy and rationalisation of medications 
 
Growing numbers of people live with multi-morbidity. As patients’ lists of co-morbidities grow, so do 
the list of an individuals’ medications. Polypharmacy presents a significant challenge for individuals 
and their clinician. Polypharmacy can be appropriate, improving quality of life and life expectancy. But 
problematic polypharmacy is a growing burden, especially for patients living with frailty.  The task of 
trying to rationalise what may be an extensive list of medications in a ten minute appointment seems 
like an impossible task.  Guidance and support specifically aimed at trainees is limited. This article 
offers a starting point for GP trainees to stimulate their own exploration of this rapidly evolving field.  
 
 INSERT CURRICULUM BOX HERE 
 
 
Polypharmacy: the challenge for trainees 
 
Polypharmacy – the use of multiple medication in a single individual – is now a routine clinical 
intervention in many patients. Appropriate Polypharmacy (see Box 1) can improve health and 
wellbeing. But Inappropriate Polypharmacy (Box 1) can create challenges for patient and GP alike. To 
illustrate what we mean by problematic polypharmacy we will consider the case of Bob – a frail patient 
with complex multimorbidity and an extensive medication list (Box 2). 
 
 INSERT BOX 1 HERE 
 
 INSERT BOX 2 HERE 
 
 
This consultation with Bob raises many questions. It appears Bob is burdened with the use of regular 
laxatives, due to his on-going opioid use, and possibly by the use of multiple antihypertensives. There 
is a question about whether his use of steroids has contributed to his dyspepsia symptoms. Can the 
steroids be titrated down in light of the PMR diagnosis? What effect has the ibuprofen had on both 
his dyspepsia and his kidney function? How can we educate the patient about the complex effects of 
these medications on the body? The patient wants antibiotics to treat his abdominal pain, now. How 
can we navigate all these issues for the patient? Above all else, how do we all this in whatever is left 
of the ten minute appointment slot? 
 
Within this array of questions, a number of core GP principles are highlighted: the importance of 
exploring and checking patient understanding and expectations, and the importance of follow up and 
review of both medication and diagnoses in patients with long-term conditions. Many of the 
challenges in polypharmacy consultations can thus be managed using good General Practice 
consultation skills.  Managing polypharmacy requires evidence-based knowledge of not only the 
mechanisms of action of medication, their side-effects and interactions, but also an understanding of 






Polypharmacy, however well intentioned, is far from benign and is associated with increased risks of 
adverse drug reactions (ADRs). A team using data from the UK Biobank project (Hanlon et al, 2018), 
identified that patients with COPD who were also suffering from other comorbidities were more likely 
than similar patients without COPD to be prescribed medication contributing towards falls, 
constipation, urinary retention, CNS depression, bleeding and renal injury. We prescribe opioids for 
pain relief which causes constipation and in turn we then prescribe laxatives for the treatment of 
constipation. However, elderly patients on laxatives are twice as likely to fall (Bloch et al, 2010). Thus 
we have increased the patients’ risk of injury and hospital admission. It is not only the use of medicines 
associated with ADRs which is of concern to the clinician. Evidence indicates 5-20% of prescriptions 
contain errors (Avery et al, 2012). The more medications a patient is taking, the higher the chance that 
one of these prescriptions will contain an error. Iatrogenic illness in patients with multi-morbidity can 
cause considerable harm. We must be mindful of how we educate patients to the risks and benefits 
of on-going medications, so that they are able to make informed decisions about the management of 
their own health conditions. 
 
Applying the principles of evidence-based practice for appropriate polypharmacy (Box 1), using the 
patient-centred consultation skills of the excellent GP, therefore offers us a good starting point for 
managing this consultation with Bob. We must not find ourselves becoming complacent with repeat 
medication prescribing and ensure that regular follow-ups are booked for patients to evaluate if long 
term prescribed medications are still in the patient’s best interests. The value of continuity of care 
comes to the fore in management of polypharmacy in General Practice.  Box 3 offers some suggestions 
for how you might approach the medication review process. 
 
 INSERT BOX 3 HERE 
 
Bob was fortunate to see an excellent GP trainee who reviewed his PMR diagnosis, was able to wean 
him off his steroid and so discontinue many of the associated medication. But Bob still had raised 
blood pressure and was prescribed multiple antihypertensives. He came back to see the trainee (who 
he now regarded as his regular GP) and reported still feeling burdened by all his tablets. “Do I really 
need all these tablets doctor?”, he asked. 
 
Bob’s question now comes into the complex territory of problematic polypharmacy (Box 2). The 
intended benefit from a medical perspective is to control BP, but Bob’s perception of benefit may 
differ. We are in the territory of the potential need for compromise between the goals of medicine 
and the goals of the patient (Duerden et al, 2013) 
 
Polypharmacy: the challenge for patients 
 
Appropriate polypharmacy applies evidence-based medical practice to improve outcomes for 
patients. But a growing evidence base also highlights that what can be appropriate from a medical 









insufficient attention has been given to the demands placed on patients when complying with taking 
multiple medications. There is growing recognition of the burden for patients of taking multiple 
medicines, even when medically appropriately prescribed.   The average number of items dispensed 
per head of population has risen from 15.5 (2007) to 20.0 (2016) (NHS Digital, 2019). This increase in 
prescribing is particularly high in the elderly with 10% of over 65’s being prescribed over 10 
simultaneous medications (Guthrie and Makubate, 2012). Patients report feeling burdened by the 
work of taking their medicines: 40% of people taking five or more medicines a day report feeling 
burdened by their medication (Krska et al, 2018), which may account for why 30-50% of medications 
are not taken as intended. When we start to think about rationalization and optimization of 
medication use to support individual patient health and wellbeing we may need to recognise that the 
compliance of the patient may be more of a key to delivering optimised care than adding a second 
antihypertensive, for example.  
 
The patient’s perspective on their medication is an important consideration for clinicians. A patient 
with too many medications may frequently miss doses. Patients who become fed up with taking too 
many pills many choose to omit ones which they feel offer no benefit. This may be particularly true 
for medications used in primary prevention where, if the medications work effectively, the patient will 
never experience any benefit from their baseline. Compliance can also be impaired by a significant 
side-effect profile, which is more likely to be the case with polypharmacy. Just because it is 
biomedically appropriate to prescribe, doesn't mean it is right for the patient. We may sometimes 
forget that there is more to our patient’s lives than taking pills! Patient experience is essential to 
developing appropriate prescribing guidelines, yet it is often overlooked. A review of reports on 
medicines optimisation published by the Royal Pharmaceutical Society (RPS), The King's Fund and 
National Institute for Health and Social Care Excellence between 2013 & 2017 (Heaton et al, 2017) 
showed a poverty of attention to the issue of the patient experience in published guidelines on 
medication use. In fact only The King’s Fund considered evidence from qualitative studies of people's 
use of medicines. This highlights an important issue with evidence-based guidelines. Broad guidelines 
are written, which aim to provide the best care for the majority of the cohort in question but this 
occurs at the expense of truly individualised care. The good clinician knows when to deviate from 




Finding solutions: rethinking how we use medicines for person-centred care 
 
So how do we find a way to better optimise medication use for our patients? Individualisation of 
prescribing is key to safe and effective prescribing in multi-morbidity. However, there is a lack of clarity 
in the literature over what direction individualisation should take (Denford et al, 2014). There is much 
research focused on the exciting field of pharmacogenetics but little attention on studies involving 
how patients and clinicians can work together to create optimised person-centred treatment plans. 
Denford et al suggest “mutually agreed tailoring” as a method of developing treatment plans with 
patients. These plans encourage patients to take a greater role in their own care including: having 
more knowledge about side-effect profiles (including advice on which side-effects may be tolerable), 







Trainees – and indeed the wider profession – need more help/guidance in IDENTIFYING who is 
burdened rather than benefited by their medicines, and so MANAGING deprescribing in situations 
when they want to discuss with patients about stopping tablets. Yet the evidence base on what to do 
and how is limited (Avery, 2019), which perhaps explains why clinicians describe finding it hard to 
tailor medication to individual patient needs in practice. A recent study examined professional barriers 
to tailoring medication (Reeve et al., 2018). GPs reported generally see their objectives as starting 
medications, in line with guidelines & patient expectations. As stopping medications requires more 
cognitive input than following well used guidelines for commencing medications, clinicians reported 
not having the headspace during busy practice times to engage with rationalisation of medications as 
much as they would like. GPs expressed concern about the lack of professional training given around 
the topic of deprescribing. Finally, physicians expressed anxiety about working outside of (and in some 
cases directly against) guidelines. Specifically in light of a growing litigation culture, GPs felt that it may 
leave them vulnerable to future consequences. 
 
There are now a number of tools being developed to support the clinician in rationalising 
medications. The evidence base demonstrating population level impact on medication load and 
mortality outcomes remains limited  (Avery & Bell, 2019) with one meta-analysis suggesting a 
decrease in medication to the tune of only 0.2 drugs per patient on average following the use of 
such tools. Another meta-analysis of randomised trials showed no overall reduction in patient 
mortality from such interventions (Page et al, 2016). However, the tools do potentially help 
individual clinicians and patients work together to safely achieve person-centred medication 
decisions.  
 
This is a rapidly evolving area. Our intention is just to give you a starting point, heads up. Some 
references/reading to help you tackle each of these challenges. Box 5 offers some tools for you to 
look at. 
 
INSERT BOX 4 HERE 
 
 
Gaps still to fill: a rapidly evolving field of practice  
 
 
Education around deprescribing is starting to be rolled out as part of junior doctor training (Poots et 
al, 2017). Tools are available to the clinician to aid with overcoming the problems associated with 
polypharmacy. These tools are varied and with some interrogation of the literature the clinician is 
likely to find a tool which fits appropriately with their own practice. These tools are far from perfect 
however. Reviewing a patent’s medication in a systematic way is a significantly time-consuming 
process and may be complicated by patients who suffer from cognitive impairment or poor 
understanding of how their medications work. Involving carers or nursing home staff may also be 
required to effectively rationalise medications and ensure they are optimised to the individual 
patient’s needs. 
 





in the GP workforce. As mentioned in the results of the survey undertaken by Reeve et al (2018) , GPs 
want to engage more with deprescribing and individualisation of prescribing but feel limited by the 
lack of time in a busy day. With 32% of GPs reporting burnout (Patel, 2019) there needs to be 
consideration of how GPs can incorporate new styles of working into practice. Neural networks and 
deep learning may offer assistance to the over-burdened GP. A team in Stanford, USA (Zitnik et al, 
2018) has developed a neural network named Decagon which looks at not only documented side-
effect profiles of medications but also at protein-protein interactions to predict side-effects associated 
with polypharmacy. Such tools, which can be used to alert the GP to interactions which they may 
otherwise miss in high-pressure short-duration consultations, will be invaluable as polypharmacy 
continues to increase in prevalence. 
 
GPs no longer work alone in practices. The rise of the multi-disciplinary team has successfully eased 
the pressure on GP workloads across the country. It need not be the case that all the work associated 
with rationalising medications and identifying those most at risk from the perils of polypharmacy falls 
entirely on the shoulders of the GP. Those practices with resident pharmacists will be able to utilise 
these staff to work pragmatically to tackle this problem. As the new GP deal contains funding for 
20,000 new staff (NHS England, 2019), this would be the time to strike when the proverbial iron is hot 
and embed rationalisation of medications and identification protocols for problematic polypharmacy 





Managing polypharmacy – especially problematic polypharmacy – is a challenge for trainees and 
qualified clinicians alike. Many of the issues arising can be dealt with using good evidence-based 
medicines management, and the core principles of good general practice including whole person 
assessment, good communication skills and continuity of care. 
 
But problematic polypharmacy also challenges medical practice to pay greater attention not only to 
the disease that people have, but to the delivery of whole person care – the principles and practice 
of expert generalist medicine. Tools and ways of working are emerging. But the needs of patients is 
evolving faster than the evidence for practice. For trainees and GPs alike,  it is important to work 





 Remember the principles of good General Practice to deliver person-centred care:  explore 
your patients’ ideas, concerns and expectations about their medicines; explicitly ask them if 
they feel burdened; invite them to work with you to identify possible areas for compromise 
 Find tool(s) that work for you in your practice: there are a growing number out there and 
they are not all the same. Have a look and choose the one that works best for you. Try it out 





 Remember you are part of a team: These are complex decisions. They need critical, 
collaborative, and thoughtful responses. Talk with your team – other GPs, pharmacists. 
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The RCGP curriculum and polypharmacy 
Professional topic guide: Improving quality, safety and prescribing 
The process of prescribing requires 
 Targeted assessment of the patient and other sources 
 An appropriately detailed understanding of the patient’s history 
 Wherever possible, an agreement with the patient and their carers on the treatment 
proposed 
 That the prescription is in the patient’s best interests, correctly and clearly prescribed, and 
accurately documented within the patient record 
 Reviewed by a suitable healthcare professional at an appropriate time 
Life Stages Topic Guide: Older adults  
As a GP, your role is to 
 Diagnose, investigate and manage older adults taking into account theories of ageing, 
differences in epidemiology and risk factors of disease in the elderly population 
 Communicate appropriately with patients, their families and carers 
 Coordinate with other organisations and professionals   
 Review medications and repeat prescriptions effectively, potentially working with 
pharmacists.  
 Ensure care promotes patients’ sense of identity, independence, personal dignity and that 
the patient is not discriminated against as a result of their age. 
Key knowledge and skills: recognising  
 Co-morbidity and physical factors disproportionately affect the health of older people and 
will influence the management of existing disease  
 A problem-based approach is important, taking in the ‘big picture’, rather than a disease- 
based approach to the care of older people 













Appropriate polypharmacy is defined as prescribing for an individual for complex conditions or for multiple 
conditions in circumstances where medicines use has been optimised and where the medicines are 
prescribed according to best evidence.  
 
 Problematic polypharmacy is defined as the prescribing of multiple medications inappropriately, or where 


















Bob is an 82 year old gentleman. He comes in on a busy Friday morning clinic to ask for some antibiotics. He states 
that he wants these for his “dicky tummy”, as his friend is on them. Further probing reveals dyspepsia symptoms. 
Bob has an extensive medication list which includes three antihypertensives, regular co-codamol, senna, lactulose 
when needed and a repeat low-level oral steroid prescription. He tells you that these are for his gout and for 
ongoing constipation. He is also taking over-the-counter ibuprofen. Reading the notes reveals that Bob saw a 
rheumatologist several years ago and was diagnosed with polymyalgia rheumatica (PMR), which was when the 
steroids were started. He has since been lost to follow-up. He has had no blood tests for past 12 months. Bob is 












Medication reviews can be done face to face with a patient, or through a review of the patient 
record. When you have completed a medication review you should clearly document in the 
patients notes for each medicine: 
 
1. Why is this person on this medication? 
Make sure you know when and why each medicine was started. Consider whether this person still 
needs this medication now and/or whether it will need to be stopped in the future? Ensure the 
reason for the medicine and planned duration of use is appropriately recoded in the patient 
record. Ask the patient if they know why they are on the medicine. 
 
2. Is each individual medicine correctly prescribed? 
If it is clinically appropriate for the medicine to be used, check: the dose, formulation, timing and 
duration of the prescription (ongoing or time bounded). Are there any errors in the writing of the 
prescription? Are alerts in place for blood tests and monitoring? 
 
3. Are all medicines prescribed showing on the patients repeat prescription list? 
For example, hospital issued medication (eg when a patient starts methotrexate) may not show 
on the GP prescription list unless specifically entered 
 
4. Red flags - do you have concerns about the collection of medicines prescribed for this 
individual? 
Check for drug interactions (which will usually show up in alerts). Are there any high risk 
medicines in the list (eg medicines that need monitoring, addictive medicines eg opiods etc)? 
Are there any potentially medically inappropriate medications? Do you need to see the patient 
face to face to explore any of these issues? 
 
5.  Is the patient using the medication as prescribed? 
Is the patient over or under using their medication? Both would prompt a request for the patient 
to come in to discuss their medication 
 
6. Are there things I am not sure about? 
Maybe unfamiliar medication or conditions; red flags associated with complex or high risk issues? 
Do I need to discuss this with an experienced GP, a pharmacist, the hospital team? And most of all 
the patient. 
 



















Contains 114 criteria (80 Stop and 34 Start) 
which either encourage the clinician to cease 
or begin medications in patients >64 years 
old.   
 
This would be useful as a tool to run 














This survey can be given to patients and asks 
them to rate a variety of factors relating to 
their experience of medication use. Questions 
are related to how medicines interfere with 
the patient’s life, side-effect profile, 
perceived effectiveness of medications and 
quality of communication with the clinician.  
 
A particularly useful tool when medicines 
seem not be to having the anticipated effect 












A very detailed resource which contains 
information on individual drugs (and 
problems associated with polypharmacy to be 
mindful of) but also contains resources for 
methodology of how the trainee should 
approach the area of rationalisation of 
medications.  
 
The 7-step approach to medicines review 
(p14) is particularly useful for the clinician as 

















A condensed tool, focusing on key areas of 
problematic prescribing found in the 
Oxfordshire area. Similar tools may exist 
within other CCGs. 
 
By focusing the guidance to align with local 
issues the tool is simple to utilise (it is only 10 
pages long) and allows the clinician to direct 






Medicines in the 












A tool focusing on rationalising medications 
as patients approach the end of life. Broken 
down into 10 broad pathological categories 
(Diabetes, Respiratory disease, Heart failure, 
Cancer, Last days of life, etc) it offers 
guidance to the clinician on which 
medications to stop, continue and even which 
medications to consider introducing.  
 
Very detailed and useful guide. By focusing on 
pathological domains rather than individual 
classes of drugs, commonly associated drugs 
are considered together, making the guidance 





Whilst rationalization of medications at the 
end of life may be done quite well in the very 
acute setting (where the patient has days or 
short weeks to live), it is often overlooked in 
the patients who may not formally be on a 
palliative pathway. Use of the question: 
“Would I be surprised if this person were to 
die in the next 12 months?” (Boyd & Murray 
2010), is useful for prompting the clinicians to 
consider engaging the patient in a discussion 
surrounding discontinuation of medications. 
 
Tools are available on the Gold Standards 
Framework website to aid clinicians in holding 
these difficult discussions. 
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